INTERVENTIONALUNKNOWNNCT02310347
Influence of a Medicinal Cannabinoid Agonist on Behavioural Responses to Food Images and Food Intake: Role of Gut Peptides
The purpose of this study is to examine the influence of a medicinal cannabinoid agonist versus placebo on behavioural and gut peptide responses to food images and food intake.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.gov↗last source update 2024-07-10
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- NA
- Enrollment
- 18 (ACTUAL)
- Start date
- 2014-12
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Design
- RANDOMIZED · CROSSOVER · BASIC SCIENCE
- Locations
- 1
- Results record
- Not present in registry snapshot
Appetite Regulation
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Conditions
No published condition report matched.
Cannabinoids and active compounds
Interventions
What was registered
DRUGdronabinol
DRUGPlacebo
Eligibility
Population and criteria
- Sex
- ALL
- Minimum age
- 18 Years
- Maximum age
- 60 Years
- Healthy volunteers
- Accepted
Inclusion criteria
- For healthy volunteers: 1. 20 ≤ BMI ≤ 25 2. Age 18-60 3. Right handed 4. Stable body weight for at least 3 consecutive months at start of study and no history of behavioural, therapeutic or surgical treatment aiming at or leading to weight loss/gain For obese subjects: 1. BMI \> 30 2. Age 18-60 3. Right handed 4. Stable body weight for at least 3 consecutive months at start of the study and no behavioural, therapeutic or surgical treatment aiming at or leading to weight loss/gain for at least 3 consecutive months For FD patients: 1. FD diagnosis according to 'Rome III' criteria 2. Age 18-60 3. Right handed 4. 5% weight loss since onset of symptoms
Exclusion criteria
- 1. Medical conditions (current or history):
- Abdominal/thoracic surgery except appendectomy
- Gastrointestinal, endocrine (especially diabetes), or neurological diseases
- Cardiovascular, respiratory, renal or urinary diseases
- Hypertension
- Food or drug allergies
- Head trauma with loss of consciousness 2. Psychiatric disorders:
- Eating disorders
- Psychotic disorders
- Major depressive disorder
- Somatoform disorder 3. Medication use:
- No history of cannabis use or any other drug of abuse for at least 12 months prior to the study
- All medication except oral contraception; 4. Known allergy to dronabinol and/or sesam oil 5. Pregnancy, plans to conceive or refusal to take adequate precaution to avoid pregnancy 6. Subjects who refuse to abstain from driving during the study
primary outcomes
primary measures
Behavioural responses to food images and food intake
Time frame: 2 years
Scores on Visual Analogue Scales
Gut peptide responses
Time frame: 2 years
Concentrations of gut peptide levels will be determined using radioimmunoassays
Publications
Locally readable linked articles
No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 8f41fe79-7fab-464a-9954-8b38f759026a
- Retrieved
- 11/09/2026, 14:15:29
- SHA-256
- ed207046ed8d71748b8de18f21dbd685e321a3a7d9d466694d809b069c5947dd